Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
Regulatory approval marks a pivotal moment for psychedelic medicine, as COMPASS Pathways prepares to test psilocybin in treatment-resistant …
The bispecific antibody earns full approval after demonstrating durable responses in heavily pre-treated patients.
Arvinas and Pfizer’s vepdegestrant becomes the first oral PROTAC therapy approved for ER-positive breast cancer, opening new avenues …
On November 14, 2024, PDS Biotech announced significant updates to its Phase 3 clinical trial design for its …
On November 13, 2024, the U.S. Food and Drug Administration (FDA) approved a novel gene therapy for aromatic …
From schizophrenia to sleep apnoea, 2024 closes with landmark approvals that could redefine treatment standards across multiple therapeutic …
With a first-in-class oral treatment approved, atopic dermatitis patients gain a novel option for disease management and improved …
Ionis Pharmaceuticals is driving progress in antisense technology, demonstrating meaningful advances in genetic disease treatment
New partnerships in real-time genomics promise faster, more accurate diagnoses for pediatric rare diseases.
A promising vaccine candidate advances efforts to combat neglected tropical diseases with mRNA innovation.
Already a subscriber? Log in